We had a wonderful time at #JPM2024, meeting with colleagues and enjoying #SanFrancisco. Great to see everyone! Until next year! #RNA #RNAvaccine #Innovation

Today, we announced the receipt of a $749,000 EZBAA contract through a partnership with BARDA under #ProjectNextGen’s Enabler’s program. The contract will support studies providing proof-of-concept data for our #RNA #vaccine LION™ platform and more. prnewswire.com/news-releases/…

Steven Reed, our Co-founder and CEO, spoke to Rick McCormick of Vial’s First In Human #podcast. They discussed Steve's journey from TB vaccines to our revolutionary repRNA vaccine platform and the future of #cancervaccines. vial.com/blog/podcast/f… #RNA #RNAvaccines

#WorldNeglectedTropicalDiseaseDay – #NeglectedTropicalDiseases (NTD) are tropical infections common in low-income populations. 1.4 billion people were affected by the 20 NTDs prioritized by the #WHO in 2018. Learn more: who.int/campaigns/worl…

#MeetTheTeam – Barbara Purmont is our HR Manager. She works hard to promote cross-functional access and communication and enjoys being a help center for our employee base. She loves being able to help and to build relationships with her coworkers. hdt.bio/team

Did you know millions lack access to basic cancer care? This #WorldCancerDay, learn about the disparities and join the movement to #CloseTheCareGap. Let's ensure everyone has a fighting chance. WorldCancerDay.org World Cancer Day #HealthEquity #WCD2024

Our CSO, Peter Berglund, Ph.D. was recently interviewed by Tyler Menichiello of Advancing RNA about common misperceptions of #cancervaccines, delivery and logistic considerations, and how to improve #RNAvaccines. Learn more: advancingrna.com/doc/rna-vaccin…

So grateful for the dedication and brilliance of the women in our lab, working tirelessly on developing #RNAvaccines for a healthier future. Today, on #InternationalDayOfWomenInScience, we celebrate their contributions and hard work! ❤️ #STEMinist bit.ly/2H8UMy6

#MeetTheTeam – Jesse Erasmus, Ph.D., our Director of Virology, finds it very rewarding to witness the evolution of our technology, which he has been working on since his Ph.D. thesis in virology at the University of Texas Medical Branch. hdt.bio/team #RNAVaccines

Happy #EmployeeAppreciationDay to our incredible team! Your dedication and passion have been the driving force behind our innovations in advancing healthcare. Thank you for all that you do! #MakeAnImpact #Innovation

Celebrating the brilliant and inspiring women at HDT Bio this International Women's Day! Today, we honor your brilliance, dedication, and commitment to science and healthcare, shaping a healthier world for all! #InternationalWomensDay #WomenInScience #IWD2024

HDT Bio recently spoke to Moira Gunn of Moira Gunn to discuss the company’s progress in #RNAvaccine development and walk her through how our revolutionary repRNA/ LION™ platform works. Listen here: bit.ly/44k4g3h

#MeetTheTeam - Adam brings 20+ years of quality management expertise in pharma & biotech, with a background in analytical chemistry and a track record of building quality systems & securing regulatory approvals. Welcome, Adam! hdt.bio/team

Partnerships with organizations and academic institutions like National Cancer Institute, University of Washington, & others to investigate our #RNA vaccine candidates for infectious disease and cancer allow us to maximize access to life saving treatments on a global scale. Learn more here: hdt.bio/partnerships/

#MeetTheTeam – Curt is a seasoned professional in research & life science, spanning discovery to clinical trials. He's served as an adjunct professor for 15+ years teaching various subjects, and he champions global health & equity. Welcome, Curt! hdt.bio/team

Want to learn more about HDT Bio’s mission and technology? Check out this episode of Slice of Healthcare’s BioBreakthroughs podcast, with our Co-founder and CEO, Steve Reed, Ph.D. sliceofhealthcare.com/32-steve-reed-… #RNAvaccine #CancerVaccine #HealthEquity

HDT Bio was recently featured in an article in Scrip, Citeline Commercial discussing how #RNA therapies and #vaccines will develop in 2024. scrip.citeline.com/SC149709/Scrip… #LookingForward #RNAvaccines #Cancervaccines #BiotechLeadership

Our CEO and Co-founder Steve Reed, Ph.D., spoke to Jeff Harmon of ‘Conversations Life Science Leaders Aren’t Having’ about the story behind HDT Bio and what makes our technology so novel. Check it out: bit.ly/3UQSk65 #RNAvaccines #Cancervaccines #BiotechLeadership

Our CSO, Peter Berglund, Ph.D. joined @MattPillar of BioProcess Online and other industry thought leaders to discuss the future of cancer vaccines. #cancervaccines #healthinnovation Watch here: youtu.be/NV3-c8Rd9Co

HDT Bio’s AMPLIFY platform reduces barriers for the distribution of our vaccines by lowering dosage requirements and increasing stability at refrigeration temperatures. Learn more about our technology here: hdt.bio/technology